Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 4/20 | 0.32 |
| ▸ | NPY1R | P25929 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 2/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5660965 | 0.94 | PPARA (0.32) | PPARANPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL5660731 | 0.91 | PPARA (0.33) | PPARANPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL5662393 | 0.89 | CA12 (0.36) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5663030 | 0.83 | — | — | |
| SCHEMBL5662525 | 0.83 | MTNR1A (0.34) | PPARA | |
| SCHEMBL5658608 | 0.81 | PPARA (0.33) | PPARATSHRNPY4RNPY1RALDH1A1 | |
| SCHEMBL5660452 | 0.80 | PPARG (0.39) | PPARA | |
| SCHEMBL5660227 | 0.77 | MCL1 (0.38) | PPARA | |
| SCHEMBL5661026 | 0.77 | MTNR1A (0.35) | PPARA | |
| Arginine SCHEMBL5662385 | 0.76 | PPARG (0.39) | PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | PPARA 251/4885ABCB11 90/4885CYP1A2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.